CSLCSLLY -0.32%73 3-1 Month Momentum % is -30.53% as of Jul. 08, 2026. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.76 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,376 Biotechnology companies, CSL ranks worse than 85.47% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-08), CSL's 3-1 Month Momentum % is -30.53%.
The industry rank for CSL's 3-1 Month Momentum % or its related term are showing as below:
CSLLY's 3-1 Month Momentum % is ranked worse than 85.47% of 1376
companies
in the Biotechnology industry
Industry Median: -8.445
vs CSLLY: -30.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CSL 3-1 Month Momentum % Related Terms
CSLLY vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, CSL's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CSL's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a 3-1 Month Momentum % of -30.53% as of Jul. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #1176 out of 1376 companies in the Biotechnology industry, placing it in the top 85.5%.
Is CSL's 3-1 Month Momentum % too high?
CSL's current 3-1 Month Momentum % is -30.53%. Based on the distribution chart, CSL ranks #1176 out of 1376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #1176 out of 1376 companies for 3-1 Month Momentum %. This places CSL in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on CSL and its competitors. CSL's current 3-1 Month Momentum % is -30.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.76, compared to a current price of $21.61 — trading 57.4% below its estimated fair value. The current 3-1 Month Momentum % is -30.53%. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For CSL (CSLLY), the current 3-1 Month Momentum % is -30.53% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.61 is trading 57.4% below its estimated GF Value™ of $50.76.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
3-1 Month Momentum %: -30.53%
GF Value™: $50.76 vs. price of $21.61 (57.4% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 